Compare CP & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CP | REGN |
|---|---|---|
| Founded | 1881 | 1988 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.7B | 79.4B |
| IPO Year | 2000 | 1995 |
| Metric | CP | REGN |
|---|---|---|
| Price | $83.25 | $775.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 24 |
| Target Price | $92.10 | ★ $819.54 |
| AVG Volume (30 Days) | ★ 2.6M | 599.7K |
| Earning Date | 04-29-2026 | 04-16-2026 |
| Dividend Yield | ★ 0.75% | 0.49% |
| EPS Growth | ★ 13.32 | 8.19 |
| EPS | 4.51 | ★ 41.48 |
| Revenue | ★ $15,078,000,000.00 | $5,872,227,000.00 |
| Revenue This Year | $8.21 | $11.69 |
| Revenue Next Year | $6.32 | $10.06 |
| P/E Ratio | ★ $18.61 | $18.65 |
| Revenue Growth | 3.66 | ★ 20.82 |
| 52 Week Low | $66.49 | $476.49 |
| 52 Week High | $89.42 | $821.11 |
| Indicator | CP | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 50.88 | 50.28 |
| Support Level | $73.31 | $740.39 |
| Resistance Level | $89.42 | $788.69 |
| Average True Range (ATR) | 1.92 | 20.92 |
| MACD | -0.80 | -1.67 |
| Stochastic Oscillator | 21.04 | 58.46 |
Canadian Pacific Kansas City is a Class I railroad operating on track that spans across most of Canada and into parts of the Midwestern and Northeastern United States. Following the April 2023 Kansas City Southern merger, CPKC operates new single-linehaul services from Canada and the Upper Midwest down through Texas, the Gulf of Mexico, and into Mexico. It also hauls cross-border and intra-Mexico freight via operating concessions on more than 3,000 miles of rail in Mexico. CPKC hauls shipments of grain, intermodal containers, energy products (like crude and frac sand), chemicals, plastics, coal, fertilizer and potash, automotive products, and a diverse mix of other merchandise.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).